Denis Soulières

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

F. Saad, A. Kapoor, S. Hotte, 2011, Current oncology.

The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement

F. Shepherd, P. Ellis, C. Butts, 2009, Current oncology.

EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.

D. Ionescu, A. Spatz, G. Chong, 2012, Current oncology.

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies

D. Huntsman, M. Tsao, S. Kamel‐Reid, 2010, Current oncology.

Canadian guideline on genetic screening for hereditary renal cell

S. Pautler, A. Pause, G. Bjarnason, 2013 .

Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma

Denis Soulières, Francis Proulx-Rocray, Francis Proulx-Rocray, 2024, Expert opinion on emerging drugs.

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

A. Finelli, G. Bjarnason, C. Kollmannsberger, 2023, JCO global oncology.

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

T. Delea, A. Khuu, D. Soulières, 2012, British Journal of Cancer.

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

K. Bélanger, L. Seymour, J. Jimeno, 2006, Annals of Oncology.